Nicaragua approves the use of the Russian vaccine Sputnik V

The Nicaraguan Ministry of Health has registered the Russian vaccine against COVID-19 Sputnik V, announced the general director of the Russian Direct Investment Fund (RDIF), Kiril Dmitriev.

As specified in a statement by the RDFI, which markets the vaccine, the registration of Sputnik V by the Nicaraguan Ministry of Health was carried out "with an accelerated procedure of 'authorization of emergency use', without carrying out additional clinical trials in the territory of the country ".

"The Government of Nicaragua, through the Ministry of Health, approved the use of the Russian vaccine to deal with the pandemic. It has been registered in Nicaragua for emergency use, as in Mexico," said the Vice President and First lady of Nicaragua Rosario Murillo.

The Vice President cited a group of countries that also approved the drug produced by Gamaleya laboratories and the Russian Fund for Direct Investment.

In addition to Mexico, Murillo mentioned Algeria, Argentina, Armenia, Belarus, Bolivia, the United Arab Emirates, Guinea, Hungary, Iran, Palestine, Paraguay, Serbia, Tunisia, Turkmenistan, and Venezuela.

"This Sputnik V vaccine has an efficacy, which has been widely disseminated, of 91.6%, and we trust God that it will be a powerful tool to protect health and life among Nicaraguan families," added the vice president.

Murillo also said that the government is making progress in negotiations with the Russian research institutes to guarantee the supply of the vaccine very soon.

In total, the vaccine was approved in 18 countries, including Russia, Belarus, Argentina, Bolivia, Serbia, Algeria, Palestine, Venezuela, Paraguay, Turkmenistan, Hungary, United Arab Emirates, Iran, the Republic of Guinea, Tunisia, Armenia, Mexico and Nicaragua.
Sputnik V, the first vaccine approved in the world on August 11, 2020, consists of two doses that are applied with an interval of 21 days. The first is based on human adenovirus type 26 and the second on recombinant human adenovirus type 5.
On February 2, the British scientific journal The Lancet published the intermediate results of phase 3 of the clinical trial of the immunizer, which confirmed its safety and high effectiveness of more than 90%. The substance completely prevents severe cases of COVID-19.